The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

I-Mab
(NASDAQ:IMAB)

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody th...

Website: https://www.i-mabbiopharma.com/

Founded: 2014

Full Time Employees: 229

CEO: Huaqiong Shen

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals Chinese

Share this website to your friends

I-Mab Days Receivable Outstanding ttm (DSO)

I-Mab Days Inventory Outstanding ttm (DIO)

I-Mab Op Cashflow Per Share ttm

I-Mab Free Cashflow Per Share ttm

I-Mab Cash Per Share ttm

I-Mab P/S ratio ttm

I-Mab (GAAP) P/E ratio ttm

I-Mab P/B ratio ttm

No extra charts and metrics for this ticker.